Frank Smart, MD
Advanced Heart Failure and Transplant Cardiology · New Orleans, LANPI 1275571341
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,826 of the $4,295 with a category attached, or 89.1%. It is spread thinly across 27 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.
Across 104 payments — averaging $41.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$791
- Abiomed$428
- Pfizer$376
- Amgen$293
- Eli Lilly$291
- Recor Medical Inc$267
- plus $2K from 21 others
Across 104 payments — averaging $1839.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$65K
- Amgen$33K
- Pfizer$31K
- Eli Lilly$17K
- Boehringer Ingelheim Pharma GmbH & Co.kg$15K
- Boehringer Ingelheim International GmbH$14K
- plus $16K from 2 others
What the payments were for
- Consulting fees$2506%
- Travel & lodging$581%
- Food & beverage$3,82689%
- Education$1614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $791 |
| Abiomed | 7 | $428 |
| Pfizer | 25 | $376 |
| Amgen | 12 | $293 |
| Eli Lilly | 7 | $291 |
| Recor Medical Inc | 2 | $267 |
| Edwards Lifesciences | 2 | $239 |
| Impulse Dynamics (USA) Inc. | 2 | $182 |
| Medtronic | 1 | $146 |
| Novo Nordisk | 5 | $138 |
| Angiodynamics, Inc. | 2 | $138 |
| Philips North America LLC | 2 | $132 |
| Penumbra, Inc. | 1 | $125 |
| Mallinckrodt Enterprises LLC | 1 | $116 |
| Janssen Scientific Affairs, LLC | 1 | $114 |
| E.r. Squibb & Sons, L.L.C. | 6 | $101 |
| Sanofi-aventis U.S. LLC | 3 | $95 |
| Merck | 4 | $78 |
| Boehringer Ingelheim | 3 | $72 |
| Amryt Pharma Holdings Ltd | 2 | $40 |
| Aegerion Pharmaceuticals, Inc. | 2 | $30 |
| Convatec Inc. | 1 | $27 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Bayer | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assurity Pacemaker$258
- CardioMEMS HF System$250
- OPTIMIZER$225
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$163
- Paradise Ultrasound Renal Denervation System$146
- Resolute$146
- Impella$127
- CARDIOMEMS$125
- Indigo System$125
- Repatha$124
- PARADISE RENAL DENERVATION SYSTEM$121
- AlphaVac$118
- ACTHAR$116
- XARELTO$114
- Stellarex Long$111
How this compares
Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 25 | $800,845 |
| EntrestoSacubitril/Valsartan | 146 | $164,230 |
| JardianceEmpagliflozin | 151 | $154,513 |
| EliquisApixaban | 131 | $143,994 |
| CamzyosMavacamten | 12 | $94,700 |
| FarxigaDapagliflozin Propanediol | 53 | $54,639 |
| XareltoRivaroxaban | 59 | $48,759 |
| Repatha SureclickEvolocumab | 52 | $28,851 |
| Praluent PenAlirocumab | 23 | $17,776 |
| VascepaIcosapent Ethyl | 18 | $9,077 |
| Ranolazine ErRanolazine | 48 | $2,678 |
| Metoprolol Succinate | 127 | $1,596 |
| Atorvastatin Calcium | 177 | $1,554 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 14 | $1,431 |
| Nifedipine ErNifedipine | 79 | $1,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $376 | $944,839156 claims |
| Boehringer IngelheimJardiance | $72 | $154,513151 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $101 | $94,70012 claims |
| AstraZenecaFarxiga | $12 | $54,63953 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in New Orleans
- Clement EiswirthNew Orleans$277K
- Senthil AnandNew Orleans$51K
- Hector VenturaNew Orleans$39K
- Sapna DesaiNew Orleans$30K
- Selim KrimNew Orleans$9K
- Hamang PatelNew Orleans$3K
- Adam LickNew Orleans$2K
- Thierry LejemtelNew Orleans$506
- Peter FailHouma$206K
- Shane PrejeanHouma$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.